SCHEMBL2309482

SCHEMBL2309482

Cc1ccc(S(=O)(=O)OCCOc2ccc(C(=O)CCC(=O)N3CCN(c4ccc(NC(=O)c5ccc6ccccc6c5)cc4)CC3)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.57
ENPP2 Q13822 2/20 0.54
RAB9A P51151 3/20 0.53
NPC1 O15118 2/20 0.50
MAPT P10636 11/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
MEN1 O00255 2/20 0.48
POLB P06746 2/20 0.48
MCL1 Q07820 1/20 0.48
ALDH1A1 P00352 4/20 0.47
USP2 O75604 2/20 0.47
HIF1A Q16665 1/20 0.47
GAA P10253 1/20 0.46
KDM4E B2RXH2 2/20 0.46
LMNA P02545 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
HTR1A P08908 1/20 0.45
ENPP1 P22413 3/20 0.45
ENPP3 O14638 2/20 0.45
CYP2C19 P33261 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12206708 0.90 KMT2A (0.61) KMT2ARAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2311130 0.89 MAPT (0.44) KMT2AENPP2RAB9ANPC1MAPT
SCHEMBL2310510 0.85 KMT2A (0.55) KMT2AENPP2RAB9ANPC1MAPT
SCHEMBL12206652 0.85 KMT2A (0.65) KMT2ARAB9ANPC1MAPTSMN1; SMN2
SCHEMBL12206707 0.85 KMT2A (0.65) KMT2ARAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2309047 0.83 MAPT (0.54) KMT2ARAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2312338 0.81 KMT2A (0.68) KMT2ARAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2308856 0.80 KMT2A (0.71) KMT2ARAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2306958 0.79 MAPT (0.54) KMT2ARAB9ANPC1MAPTSMN1; SMN2
SCHEMBL12206714 0.79 KMT2A (0.47) KMT2ARAB9AMAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110250135-A1 Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-10-13 US disclosed
EP-2350000-A1 PIPERAZINE DERIVATIVES FOR BINDING AND IMAGING AMYLOID PLAQUES AND THEIR USE Bayer Schering Pharma Aktiengesellschaft (DE) 2011-08-03 EP disclosed
WO-2010028776-A1 PIPERAZINE DERIVATIVES FOR BINDING AND IMAGING AMYLOID PLAQUES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-03-18 WO disclosed
EP-2163541-A1 Piperazine derivatives for binding and imaging amyloid plaques and their use Bayer Schering Pharma Aktiengesellschaft (DE) 2010-03-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110250135-A1 Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use APP, APBA1, PSEN1 KMT2A 4443/4885ENPP2 835/4885RAB9A 3441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.